U
67.92
6.91 (11.33%)
| Previous Close | 61.01 |
| Open | 61.65 |
| Volume | 2,574,211 |
| Avg. Volume (3M) | 3,293,714 |
| Market Cap | 4,184,128,000 |
| Price / Earnings (Forward) | 27.93 |
| Price / Sales | 196.41 |
| Price / Book | 2.83 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Operating Margin (TTM) | -2,815.25% |
| Diluted EPS (TTM) | -4.38 |
| Quarterly Revenue Growth (YOY) | -81.50% |
| Total Debt/Equity (MRQ) | 1,522.46% |
| Current Ratio (MRQ) | 11.99 |
| Operating Cash Flow (TTM) | -166.25 M |
| Levered Free Cash Flow (TTM) | -122.89 M |
| Return on Assets (TTM) | -15.64% |
| Return on Equity (TTM) | -241.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | uniQure N.V. | Bullish | Bullish |
AIStockmoo Score
1.0
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 1.00 |
|
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.09% |
| % Held by Institutions | 91.95% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 110.00 (HC Wainwright & Co., 61.96%) | Buy |
| Median | 76.00 (11.90%) | |
| Low | 56.00 (Goldman Sachs, -17.55%) | Hold |
| Average | 76.67 (12.88%) | |
| Total | 8 Buy, 1 Hold | |
| Avg. Price @ Call | 51.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 06 Oct 2025 | 110.00 (61.96%) | Buy | 52.91 |
| 24 Sep 2025 | 70.00 (3.06%) | Buy | 47.50 | |
| Wells Fargo | 02 Oct 2025 | 80.00 (17.79%) | Buy | 54.50 |
| 25 Sep 2025 | 65.00 (-4.30%) | Buy | 52.65 | |
| Cantor Fitzgerald | 25 Sep 2025 | 80.00 (17.79%) | Buy | 52.65 |
| Chardan Capital | 25 Sep 2025 | 76.00 (11.90%) | Buy | 52.65 |
| 08 Sep 2025 | 35.00 (-48.47%) | Buy | 17.43 | |
| Goldman Sachs | 25 Sep 2025 | 56.00 (-17.55%) | Hold | 52.65 |
| Guggenheim | 25 Sep 2025 | 95.00 (39.87%) | Buy | 52.65 |
| Mizuho | 25 Sep 2025 | 60.00 (-11.66%) | Buy | 52.65 |
| Leerink Partners | 24 Sep 2025 | 68.00 (0.12%) | Buy | 47.50 |
| Stifel | 24 Sep 2025 | 65.00 (-4.30%) | Buy | 47.50 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Sep 2025 | Announcement | uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares |
| 25 Sep 2025 | Announcement | uniQure Announces Pricing of Upsized $300 Million Public Offering |
| 24 Sep 2025 | Announcement | uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding |
| 24 Sep 2025 | Announcement | uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease |
| 24 Sep 2025 | Announcement | uniQure Announces $200 Million Proposed Public Offering |
| 05 Sep 2025 | Announcement | uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |